Geneos Wealth Management Inc. - INTERCEPT PHARMACEUTICALS IN ownership

Quarter-by-quarter ownership
Geneos Wealth Management Inc. ownership history of INTERCEPT PHARMACEUTICALS IN
ValueSharesWeighting
Q3 2023$7,416
+67.6%
4000.0%0.00%
Q2 2023$4,424
-17.6%
4000.0%0.00%
Q1 2023$5,372
+8.6%
4000.0%0.00%
Q4 2022$4,948
-1.0%
4000.0%0.00%
Q3 2022$5,0000.0%4000.0%0.00%
Q2 2022$5,000
-16.7%
4000.0%0.00%
Q1 2022$6,0000.0%4000.0%0.00%
Q4 2021$6,0000.0%4000.0%0.00%
Q3 2021$6,000
-14.3%
4000.0%0.00%
Q2 2021$7,0000.0%4000.0%0.00%
Q1 2021$7,000
-22.2%
4000.0%0.00%
Q4 2020$9,000
-43.8%
4000.0%0.00%
-100.0%
Q3 2020$16,000
-46.7%
4000.0%0.00%
-50.0%
Q2 2020$30,000
+15.4%
4000.0%0.00%0.0%
Q1 2020$26,000
-46.9%
4000.0%0.00%
-33.3%
Q4 2019$49,000
+96.0%
4000.0%0.00%
+200.0%
Q3 2019$25,000
-19.4%
4000.0%0.00%
-50.0%
Q2 2019$31,000
-29.5%
4000.0%0.00%
-33.3%
Q1 2019$44,000
-21.4%
400
-33.3%
0.00%
-25.0%
Q4 2018$56,000
-11.1%
600
+20.0%
0.00%0.0%
Q3 2018$63,000
+90.9%
500
+25.0%
0.00%
+33.3%
Q2 2018$33,000
+37.5%
4000.0%0.00%
+50.0%
Q1 2018$24,000
+4.3%
4000.0%0.00%0.0%
Q4 2017$23,0000.0%4000.0%0.00%0.0%
Q3 2017$23,0004000.00%
Other shareholders
INTERCEPT PHARMACEUTICALS IN shareholders Q4 2023
NameSharesValueWeighting ↓
Sarissa Capital Management LP 635,300$53,308,00010.69%
Senvest Management, LLC 976,127$81,907,0005.65%
Melqart Asset Management (UK) Ltd 390,600$32,775,0002.80%
Asymmetry Capital Management, L.P. 25,918$2,175,0002.14%
Elk Creek Partners, LLC 386,397$32,423,0001.78%
BB BIOTECH AG 545,719$45,791,0001.32%
ALTRINSIC GLOBAL ADVISORS LLC 383,166$32,151,0001.27%
DLD Asset Management, LP 129,000$10,824,0000.82%
Opus Point Partners Management, LLC 3,998$335,0000.73%
Virtus ETF Advisers LLC 8,970$753,0000.67%
View complete list of INTERCEPT PHARMACEUTICALS IN shareholders